Table 1 Demographic characteristics of patient with ILD in the UCSF scleroderma cohort
Overall | Men (47) | Women (162) | P value | |
|---|---|---|---|---|
Hispanic, n (%) | 46 (22) | 8 (17) | 38 (23) | 0.12 |
Race, n (%) | 0.30 | |||
Non-Hispanic White | 103 | 25 (53) | 78 (48) | |
Hispanic | 43 | 8 (17) | 35 (22) | |
Asian | 33 | 6 (12) | 27 (16) | |
Black/African American | 22 | 7 (15) | 15 (9) | |
Pacific Islander/Hawaiian | 2 | 0 | 2 (1) | |
Other | 6 | 1 (2) | 5 (3) | |
Age at enrollment (SD) | 54.65 (12.8) | 50.9 (11.6) | 51.8 (13.1) | 0.65 |
Anti Scl-70 antibody, n (%) | 81 (38) | 20 (43) | 61 (38) | 0.54 |
Anticentromere antibody, n (%) | 10 (5) | 2 (4) | 8 (5) | 0.98 |
Smoking status, n (%) | 0.15 | |||
Never | 136 (64) | 25 (53) | 111 (68) | |
Current | 4 (2) | 1 (2) | 3 (2) | |
Former | 71 (34) | 21 (45) | 48 (30) | |
BMI, kg/m2, mean (SD) | 23.59 (4.8) | 24.6 (4.5) | 23.3 (4.8) | 0.11 |
Diffuse SSc, n (%) | 86 (41) | 22 (47) | 64 (40) | 0.37 |
Use of Immunosuppression, n (%) | 179 (85) | 43 (91) | 135 (83) | 0.16 |
Presence of pulmonary hypertension, n (%) | 51 (24) | 14 (30) | 37 (22) | 0.564 |
Worst Modified Rodnan skin score [IQR] | 3 [3–9] | 5 [3–11] | 3 [3–8] | 0.19 |
Time from first Raynaud’s symptom onset to ILD diagnosis, years, median [IQR] | 4.4 [1.2–10] | 2.9 [1.4–5.7] | 4.7[1-11.9] | 0.17 |
Time from first non-Raynaud’s symptom onset to ILD diagnosis, years, median [IQR] | 2.8 [0.7–6.1] | 2.3 [0.7-5] | 3 [0.7–6.3] | 0.27 |
Initial FCV, % predicted, mean (SD) | 71.3 (19.9) | 66.3 (21.1) | 72.8 (19.4) | 0.06 |
Initial DLCO, corrected for hemoglobin, % predicted, mean (SD) | 55.5 (22.3) | 53.2 (24.3) | 56.2 (21.7) | 0.43 |